TABLE 2.
Associations of Infants’ Clinical Characteristics After End of Treatment Course or 3 Weeks After Sample Collection and Presence of Postnatal CMV Infection and Antiviral Treatment
| CMVPNT vs. NEG | CMVPT vs. NEG | ||||||
|---|---|---|---|---|---|---|---|
| NEG (n = 50) | CMVPNT (n = 26) | CMVPT (n = 27) | OR (95% CI) | P | OR (95% CI) | P | |
| Hepatosplenomegaly [n (%)] | 6/40 (15) | 0/13 (0) | 9/20 (45) | – | 0.057a | 4.64 (1.35–15.97) | 0.015 |
| Jaundice [n (%)] | 12/40 (30) | 0/13 (0) | 5/21 (23.8) | – | 0.005a | 0.73 (0.22–2.45) | 0.609 |
| Me (IQR; n) AST [μkat/l] | 3.65 (2.47–4.11; 10) | 2.3 (1.46–3.13; 2) | 2.79 (0.92–3.6; 12) | 0.58 (0.19–1.75) | 0.336 | 0.67 (0.36–1.25) | 0.207 |
| Me (IQR; n) ALT [μkat/l] | 1.21 (0.69–1.87; 10) | 1.2 (0.69–1.71; 2) | 0.87 (0.58–1.31; 12) | 0.91 (0.09–9.19) | 0.935 | 0.48 (0.12–1.93) | 0.301 |
| Me (IQR; n) γ–GT [μkat/l] | 1.94 (1.79–5.9; 10) | 4.3 (4.19–4.41; 2) | 3.43 (2.12–6.5; 11) | 1.16 (0.62–2.16) | 0.646 | 1.17 (0.81–1.7) | 0.408 |
| Me (IQR; n) direct bilirubin [μmol/l] | 49 (42–79; 9) | 25.5 (0–51; 2) | 66.5 (32–154; 8) | 0.97 (0.91–1.03) | 0.321 | 1.01 (0.99–1.03) | 0.332 |
| Me (IQR; n) total bilirubin [μmol/l] | 72 (69–121; 9) | 42 (15–69; 2) | 91.5 (46–183.5; 8) | 0.97 (0.92–1.03) | 0.282 | 1.01 (0.99–1.02) | 0.495 |
| Me (IQR; n) platelet count [×109/l] | 260 (192–391; 19) | 223 (157–335; 11) | 168 (120–253; 21) | 1 (0.99–1) | 0.384 | 0.99 (0.98–1) | 0.012 |
| Me (IQR; n) leukocyte count [×109/l] | 9.1 (7.75–15.3; 16) | 7.8 (5.6–11.8; 11) | 7.2 (5–11.9; 21) | 0.92 (0.8–1.06) | 0.273 | 0.95 (0.86–1.04) | 0.273 |
| Me (IQR; n) neutrophils count [×109/l] | 4.9 (3.1–8.1; 9) | 1.9 (1.3–3.2; 10) | 1.5 (0.9–3.1; 15) | 0.79 (0.54–1.17) | 0.24 | 0.96 (0.85–1.09) | 0.569 |
| Me (IQR; n) CRP [mg/l] | 5 (3–10; 11) | 5 (5–14; 9) | 14 (5–29; 14) | 0.98 (0.93–1.04) | 0.55 | 1 (0.98–1.03) | 0.721 |
| Me (IQR) minimal FiO2 | 0.26 (0.22–0.4) | 0.22 (0.22–0.24) | 0.3 (0.24–0.7) | 0 (0–2.94) | 0.077 | 8.53 (0.81–89.4) | 0.074 |
| Me (IQR) maximal FiO2 | 0.3 (0.23–0.45) | 0.23 (0.22–0.27) | 0.34 (0.25–0.7) | 0 (0–1.62) | 0.067 | 6.04 (0.67–54.8) | 0.11 |
CI, confidence interval; CMVPNT, CMV positive without antiviral treatment group; CMVPT, CMV positive on antiviral therapy group; IQR, interquartile range; Me, median; n, number of subjects; NEG, CMV negative group (control group); OR, odds ratio.
a
Odds ratio test.